Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657

The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology

Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989

2016 Alzheimer's disease facts and figures

Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069

Molecular dissection of reactive astrogliosis and glial scar formation

Sofroniew, M. V. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.08.002 · Cited by 2,594

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380

2015 Alzheimer's disease facts and figures

Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635

The therapeutic potential of monoamine oxidase inhibitors

Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363

Untitled work

Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284

Studies on free radicals, antioxidants, and co-factors.

Rahman, K. (2007) · PubMed Central · Cited by 995

The GABAergic deficit hypothesis of major depressive disorder

Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934

Aldehyde Sources, Metabolism, Molecular Toxicity Mechanisms, and Possible Effects on Human Health

O'Brien, P. J., Siraki, A. G., & Shangari, N. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440591002183 · Cited by 738

DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study

Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.08.154 · Cited by 656

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641

Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors

Son, S.-Y., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E., & Tsukihara, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710626105 · Cited by 623

Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs

Binda, C., Wang, J., Pisani, L., Caccia, C., Carotti, A., Salvati, P., Edmondson, D. E., & Mattevi, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070677y · Cited by 607

Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B

De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505975102 · Cited by 527

Molecular Mechanisms of Acrolein Toxicity: Relevance to Human Disease

Moghe, A., Ghare, S., Lamoreau, B., Mohammad, M., Barve, S., McClain, C., & Joshi-Barve, S. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu233 · Cited by 511

Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11 C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11 C-Pittsburgh Compound B and 18 F-FDG

Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442

Inflammatory process in Alzheimer's Disease

Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients With Parkinson Disease and Motor Fluctuations: The PRESTO Study

(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418

Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography

Saura, J., Luque, J. M., Cesura, A. M., Prada, M. D., Chan-Palay, V., Huber, G., Löffler, J., & Richards, J. G. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90311-5 · Cited by 382

The importance of norepinephrine in depression

Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373

Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution

Niemann, B., Rohrbach, S., Miller, M. R., Newby, D. E., Fuster, V., & Kovacic, J. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.043 · Cited by 353

Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase

Marchitti, S. A., Deitrich, R. A., & Vasiliou, V. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.1 · Cited by 280

Monoamine Oxidase-B Inhibition in Alzheimer's Disease

Riederer, P. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00106-2 · Cited by 254

The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia

Cohen, S. M., Tsien, R. W., Goff, D. C., & Halassa, M. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.026 · Cited by 232

Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels

Schedin-Weiss, S., Inoue, M., Hromadkova, L., Teranishi, Y., Yamamoto, N. G., Wiehager, B., Bogdanovic, N., Winblad, B., Sandebring-Matton, A., Frykman, S., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0279-1 · Cited by 230

Oxidation of amines by flavoproteins

Fitzpatrick, P. F. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.07.019 · Cited by 219

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease

Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216

Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer’s disease (Review)

CAI, Z. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2040 · Cited by 212

Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography

Gulyás, B., Pavlova, E., Kása, P., Gulya, K., Bakota, L., Várszegi, S., Keller, É., Horváth, M. C., Nag, S., Hermecz, I., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.013 · Cited by 202

Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease

Thomas, T. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00100-7 · Cited by 201

N‐Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury

Demougeot, C., Garnier, P., Mossiat, C., Bertrand, N., Giroud, M., Beley, A., & Marie, C. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00285.x · Cited by 194

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

Balu, D. T., Hoshaw, B. A., Malberg, J. E., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.023 · Cited by 194

Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease

Bradley, M. A., Markesbery, W. R., & Lovell, M. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.016 · Cited by 193

Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: Differential regulation of specific exons by antidepressants and corticosterone

Dwivedi, Y., Rizavi, H. S., & Pandey, G. N. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.12.058 · Cited by 192

Nutraceuticals in Neurological Disorders

Makkar, R., Behl, T., Bungau, S., Zengin, G., Mehta, V., Kumar, A., Uddin, M. S., Ashraf, G. M., Abdel-Daim, M. M., Arora, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124424 · Cited by 181

Privileged scaffolds as MAO inhibitors: Retrospect and prospects

Tripathi, A. C., Upadhyay, S., Paliwal, S., & Saraf, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.003 · Cited by 170

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa

Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390106 · Cited by 170

Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications

Edmondson, D. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113190990406 · Cited by 168

Selegiline for Alzheimer's disease

Birks, J., & Flicker, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000442 · Cited by 162

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort

on behalf of the CAN-BIND Investigator Team, Lam, R. W. M., Milev, R. V., Rotzinger, S., Andreazza, A. C., Blier, P., Brenner, C. A., Daskalakis, Z. J., Dharsee, M., Downar, J. H., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0785-x · Cited by 155

Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 154

An Imbalance Between Excitatory and Inhibitory Neurotransmitters in Amyotrophic Lateral Sclerosis Revealed by Use of 3-T Proton Magnetic Resonance Spectroscopy

Foerster, B. R., Pomper, M. G., Callaghan, B. C., Petrou, M., Edden, R. A. E., Mohamed, M. A., Welsh, R. C., Carlos, R. C., Barker, P. B., & Feldman, E. L. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.234 · Cited by 150

Protective effects of hesperidin and diosmin against acrylamide-induced liver, kidney, and brain oxidative damage in rats

Elhelaly, A. E., Albasher, G. I., Alfarraj, S. A., Almeer, R., Bahbah, E. I., Fouda, M. M. A., BUNGAU, S. G., Aleya, L., & Abdel‐Daim, M. M. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-06660-3 · Cited by 146

Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease

Wang, L., Esteban, G., Ojima, M., Bautista‐Aguilera, Ó. M., Inokuchi, T., Moraleda, I., Iriepa, I., Samadi, A., Youdim, M. B. H., Romero, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.078 · Cited by 143

Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders

Kumar, B., Sheetal, S., Mantha, A. K., & Kumar, V. (2016) · RSC Advances · doi:10.1039/c6ra00302h · Cited by 139

Origins of Serum Semicarbazide-Sensitive Amine Oxidase

Stolen, C., Yegutkin, G. G., Kurkijärvi, R., Bono, P., Alitalo, K. K., & Jalkanen, S. (2004) · Circulation Research · doi:10.1161/01.res.0000134630.68877.2f · Cited by 138

Donepezil Use in Alzheimer Disease

Barner, E. L., & Gray, S. L. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17150 · Cited by 137

Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening

Novaroli, L., Reist, M., Favre, E., Carotti, A., Catto, M., & Carrupt, P. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.06.043 · Cited by 135

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

Waibel, S., Reuter, A., Malessa, S., Blaugrund, E., & Ludolph, A. C. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0481-5 · Cited by 134

Potential implications of endogenous aldehydes in β‐amyloid misfolding, oligomerization and fibrillogenesis

Chen, K., Maley, J., & Yu, P. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04181.x · Cited by 131

Conventional and new antidepressant drugs in the elderly

Gareri, P., Falconi, U., Fazio, P. D., & Sarro, G. D. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00050-7 · Cited by 125

Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery

Ramsay, R. R. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612805219978 · Cited by 121

Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease

Kennedy, B. P., Ziegler, M. G., Alford, M. F., Hansen, L. A., Thal, L. J., & Masliah, E. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0828-6 · Cited by 116

Monoamine Oxidase and Mitochondrial Respiration

Cohen, G., & Kesler, N. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732310.x · Cited by 115

When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer's disease

Avila-Muñoz, E., & Arias, C. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.07.004 · Cited by 114

Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer’s Disease in Mice, Observed by in Vivo Two-Photon Imaging

Kim, D., Baik, S. H., Kang, S., Cho, S. W., Bae, J., Cha, M.-Y., Sailor, M. J., Mook‐Jung, I., & Ahn, K. H. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00309 · Cited by 112

Lipids' peroxidation markers in Alzheimer's disease and vascular dementia

Gustaw‐Rothenberg, K., Kowalczuk, K., & Stryjecka‐Zimmer, M. (2009) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2009.00571.x · Cited by 109

Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats

Albasher, G. I., Abdel‐Daim, M. M., Almeer, R., Ibrahim, K. A., Hamza, R. Z., BUNGAU, S. G., & Aleya, L. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-07344-8 · Cited by 105

Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients

Emilsson, L., Saetre, P., Balciuniene, J., Castensson, A., Cairns, N. J., & JAZIN, E. E. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00307-5 · Cited by 102

Vascular adhesion protein-1: Role in human pathology and application as a biomarker

Pannecoeck, R., Serruys, D., Benmeridja, L., Delanghe, J., van Geel, N., Speeckaert, R., & Speeckaert, M. M. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1050714 · Cited by 99

The discovery of antidepressants: A winding path

Pletscher, A. (1991) · Cellular and Molecular Life Sciences · doi:10.1007/bf02041242 · Cited by 99

Selegiline: a molecule with innovative potential

Tábi, T., Vécsei, L., Youdim, M. B. H., Riederer, P. F., & Szökő, É. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02082-0 · Cited by 99

Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease

Nam, D. T., Arseneault, M., Murthy, V., & Ramassamy, C. (2010) · Current Molecular Pharmacology · doi:10.2174/1874-470211003020066 · Cited by 97

Lipid peroxidation products and their role in neurodegenerative diseases

Taso, O. S., Philippou, Α., Moustogiannis, A., Zevolis, E., & Koutsilieris, M. (2019) · Annals of Research Hospitals · doi:10.21037/arh.2018.12.02 · Cited by 97

Monoamine oxidase B in brains from patients with Alzheimer's disease: A biochemical and autoradiographical study

Jossan, S. S., Gillberg, P., Gottfries, C. G., Karlsson, I., & Oreland, L. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90098-9 · Cited by 95

5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.

Cochet, M., Donneger, R., Cassier, E., Gaven, F., Lichtenthaler, S., Marin, P., Bockaert, J., Dumuis, A., & Claeysen, S. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300095t · Cited by 92

Alleviation of Drugs and Chemicals Toxicity: Biomedical Value of Antioxidants

Abdel‐Daim, M. M., Abo‐EL‐Sooud, K., Aleya, L., BUNGAU, S. G., Najda, A., & Saluja, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6276438 · Cited by 92

Vascular Adhesion Protein-1 Inhibition Provides Antiinflammatory Protection after an Intracerebral Hemorrhagic Stroke in Mice

Ma, Q., Manaenko, A., Khatibi, N. H., Chen, W., Zhang, J. H., & Tang, J. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.167 · Cited by 91

Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease

Borroni, E., Bohrmann, B., Grueninger, F., Prinssen, E. P. M., Navé, S., Loetscher, H., Chinta, S. J., Rajagopalan, S., Rane, A., Siddiqui, A., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241653 · Cited by 90

Acrolein induces Alzheimer's disease-like pathologies in vitro and in vivo

Huang, Y., Jin, M.-H., Pi, R., Zhang, J., Ouyang, Y., Chao, X., Chen, M.-H., Liu, P., Yu, J., Ramassamy, C., et al. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.023 · Cited by 89

Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer’s disease

Unzeta, M., Solé, M., Boada, M., & Hernández‐Guillamón, M. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0701-0 · Cited by 88

Adaptive Plasticity in Tachykinin and Tachykinin Receptor Expression after Focal Cerebral Ischemia Is Differentially Linked to GABAergic and Glutamatergic Cerebrocortical Circuits and Cerebrovenular Endothelium

Stumm, R. K., Culmsee, C., Schäfer, M. K.-H., Krieglstein, J., & Weihe, E. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00798.2001 · Cited by 85

Does phenylethylamine act as an endogenous amphetamine in some patients?

Janssen, P. A. J., Leysen, J. E., Megens, A. A. H. P., & Awouters, F. H. L. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001522 · Cited by 84

Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death

Burke, W. J., Li, S. W., Schmitt, C. A., Xia, P., Chung, H. D., & Gillespie, K. N. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01211-6 · Cited by 83

Altered excitatory-inhibitory balance within somatosensory cortex is associated with enhanced plasticity and pain sensitivity in a mouse model of multiple sclerosis

Potter, L. E., Paylor, J. W., Suh, J. S., Tenorio, G., Caliaperumal, J., Colbourne, F., Baker, G. B., Winship, I. R., & Kerr, B. J. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0609-4 · Cited by 82

Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal

Romano, A., Serviddio, G., Calcagnini, S., Villani, R., Giudetti, A. M., Cassano, T., & Gaetani, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.046 · Cited by 79

Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history

Streit (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00022 · Cited by 76

Phenelzine Mitochondrial Functional Preservation and Neuroprotection after Traumatic Brain Injury Related to Scavenging of the Lipid Peroxidation-Derived Aldehyde 4-Hydroxy-2-Nonenal

Singh, I. N., Gilmer, L. K., Miller, D. M., Cebak, J. E., Wang, J. A., & Hall, E. D. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.211 · Cited by 76

Altered GABAergic Signaling in Brain Disease at Various Stages of Life

Kim, Y. S., & Yoon, B. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.3.122 · Cited by 76

Methylglyoxal Induces Tau Hyperphosphorylation via Promoting AGEs Formation

Li, X., Xie, J., Jiang, X., Lv, B.-L., Cheng, X., Du, L., Zhang, J. Y., Wang, J., & Zhou, X. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8191-0 · Cited by 74

A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

Weinstock, M., Gorodetsky, E. K., Poltyrev, T., Gross, A., Sagi, Y., & Youdim, M. B. H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00053-8 · Cited by 72

From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease

Zheng, H., Amit, T., Bar‐Am, O., Fridkin, M., Youdim, M. B. H., & Mandel, S. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120013 · Cited by 63

Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches

Hong, R.-Y., & Li, X. (2018) · MedChemComm · doi:10.1039/c8md00446c · Cited by 63

A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?

Clarke, C. E. (2004) · Movement Disorders · doi:10.1002/mds.20057 · Cited by 59

Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease

Mück‐Šeler, D., Presečki, P., Mimica, N., Mustapić, M., Pivac, N., Perhoč, A. B., Erjavec, G. N., & Folnegović-Šmalc, V. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.004 · Cited by 58

Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic–pituitary–adrenal axis in male and female prenatally stressed rats

Poltyrev, T., Gorodetsky, E. K., Bejar, C., Schorer-Apelbaum, D., & Weinstock, M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2229-z · Cited by 56

The Serum Protein and Lipid Oxidation Marker Levels in Alzheimers Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy

Sinem, F., Konukoğlu, D., Gokhan, E., Melda, B., Orhan, Y., & Filiz, M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383822 · Cited by 54

On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B

McDonald, G. R., Olivieri, A., Ramsay, R. R., & Holt, A. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.09.001 · Cited by 53

Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia

Leker, R. R., & Neufeld, M. Y. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00170-x · Cited by 52

Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer’s disease: a tribute to Moussa Youdim

Weinreb, O., Mandel, S. A., Bar‐Am, O., & Amit, T. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0597-6 · Cited by 51

Neuroprotective Effect of Cyclooxygenase Inhibitors in ICV-STZ Induced Sporadic Alzheimer’s Disease in Rats

Dhull, D. K., Jindal, A., Dhull, R. K., Aggarwal, S., Bhateja, D., & Padi, S. S. V. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9583-6 · Cited by 50

Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex

Quartey, M. O., Nyarko, J. N. K., Pennington, P. R., Heistad, R. M., Klassen, P. C., Baker, G. B., & Mousseau, D. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00419 · Cited by 49

The inhibitor of semicarbazide‐sensitive amine oxidase, PXS‐4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model

Jarnicki, A., Schilter, H. C., Liu, G., Wheeldon, K., Essilfie, A., Foot, J. S., Yow, T. T., Jarolimek, W., & Hansbro, P. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13573 · Cited by 48

Pharmacotherapy of social anxiety disorder

Schneier, F. R. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.534983 · Cited by 41

Biogenic aldehyde-mediated mechanisms of toxicity in neurodegenerative disease

Cagle, B. S., Crawford, R. A., & Doorn, J. A. (2018) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2018.12.002 · Cited by 41

Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.

Kumagae, Y., Matsui, Y., & Iwata, N. (1991) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.55.121 · Cited by 40

Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis

O’Rourke, A. M., Wang, E. Y., Salter–Cid, L., Huang, L. Y., Miller, A., Podar, E. M., Gao, H., Jones, D. S., & Linnik, M. D. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0699-3 · Cited by 39

Antioxidant Effect of Phenelzine on MPP+-Induced Cell Viability Loss in Differentiated PC12 Cells

Lee, C. S., Han, E. S., & Lee, W. B. (2003) · Neurochemical Research · doi:10.1023/a:1026119708124 · Cited by 33

Analgesic and Anti-Inflammatory Effects of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models of the Mouse

Horváth, Á. I., Menghis, A., Botz, B., Borbély, É., Kemény, Á., Tékus, V., Csepregi, J. Z., Mócsai, A., Juhász, T., Zákány, R., et al. (2017) · Scientific Reports · doi:10.1038/srep39863 · Cited by 33

Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine

Baker, G. B., Matveychuk, D., MacKenzie, E. M., Holt, A., Wang, Y., & Kar, S. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.003 · Cited by 33

An Intensified Acrolein Exposure Can Affect Memory and Cognition in Rat

Khoramjouy, M., Naderi, N., Kobarfard, F., Heidarli, E., & Faizi, M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00278-x · Cited by 33

Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration

García-Fuster, M. J., & García-Sevilla, J. A. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4342-6 · Cited by 32

Phenelzine, a cell adhesion molecule L1 mimetic small organic compound, promotes functional recovery and axonal regrowth in spinal cord-injured zebrafish

Li, R., Sahu, S. S., & Schachner, M. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.05.013 · Cited by 30

Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease

Zheng, H., Fridkin, M., & Youdim, M. B. H. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0293-1 · Cited by 28

The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in parkinson's disease

Youdim, M. B. H., & Riederer, P. F. (1993) · Movement Disorders · doi:10.1002/mds.870080504 · Cited by 27

Immunohistochemical study of semicarbazide‐sensitive amine oxidase/vascular adhesion protein‐1 in the hippocampal vasculature: Pathological synergy of Alzheimer's disease and diabetes mellitus

Valente, T., Gella, A., Solé, M., Durany, N., & Unzeta, M. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23092 · Cited by 26

Calbindin D-28k and Monoamine Oxidase A Immunoreactive Neurons in the Nucleus Basalis of Meynert in Senile Dementia of the Alzheimer Type and Parkinson's Disease

Chan‐Palay, V., Höchli, M., Savaskan, E., & Hungerecker, G. (1993) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107290 · Cited by 25

Limited Potentiation of Blood Pressure in Response to Oral Tyramine by the Anti-Parkinson Brain Selective Multifunctional Monoamine Oxidase-AB Inhibitor, M30

Gal, S., Abassi, Z. A., & Youdim, M. B. H. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9128-8 · Cited by 24

Phenelzine: An Old Drug That May Hold Clues to The Development of New Neuroprotective Agents

MacKenzie, E. M., Song, M.-S., Dursun, S. M., Tomlinson, S. E., Todd, K. G., & Baker, G. B. (2010) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2010.11790656 · Cited by 21

The 4‑hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions

Mustafa, A., Alfaqih, M. A., & Al-Shboul, O. A. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6419 · Cited by 21

Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish

Joseph, T. P., Jagadeesan, N., Sai, L., Lin, S. L., Sahu, S. S., & Schachner, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00458 · Cited by 20

Phenelzine reduces the oxidative damage induced by peroxynitrite in plasma lipids and proteins

Mustafa, A., Al-Shboul, O. A., Alfaqih, M. A., Alqudah, M., & Al‐Dwairi, A. (2017) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2017.1415939 · Cited by 16

Theobromine and related methylxanthines as inhibitors of Primary Amine Oxidase

Shanahan, P., O’Sullivan, J., Tipton, K. F., Kinsella, G. K., Ryan, B. J., & HENEHAN, G. T. M. (2018) · Journal of Food Biochemistry · doi:10.1111/jfbc.12697 · Cited by 16

Comparison of phenelzine and geometric isomers of its active metabolite, β-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine

Matveychuk, D., Nunes, E. A., Ullah, N., Velázquez‐Martínez, C. A., MacKenzie, E. M., & Baker, G. B. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0978-0 · Cited by 12

Lazabemide for the long-term treatment of Alzheimer's disease

Magni, G., & Meibach, R. C. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80017-0 · Cited by 10

Pargyline Conjugate-Induced Long-Term Activation of Monoamine Oxidase as an Immunological Model for Depression

Danilova, R. A., Moskvityna, T. A., Obukhova, M. F., Belopolskaya, M. V., & Ашмарин, И. П. (1999) · Neurochemical Research · doi:10.1023/a:1020764504462 · Cited by 8

The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions

Alfaqih, M. A., Mustafa, A., & Al-Shboul, O. A. (2018) · Endocrine Abstracts · doi:10.1530/endoabs.56.p640 · Cited by 5

Aducanumab—Hope or Disappointment for Alzheimer’s Disease

Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054367 · Cited by 73

Machine learning in Alzheimer’s disease drug discovery and target identification

Geng, C., Wang, Z., & Tang, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102172 · Cited by 34

Sirtuin dysregulation in Parkinson's disease: Implications of acetylation and deacetylation processes

Dhiman, S., Mannan, A., Taneja, A., Mohan, M., & Singh, T. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122537 · Cited by 25